Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer

BACKGROUND AND OBJECTIVES: Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-α (PDGFRα). In a randomized phase II study, olaratumab plus doxorubicin met its predefined primary endpoint for progression-free survival and achieved a highly signi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Pharmacokinet
Autors principals: Mo, Gary, Baldwin, John R., Luffer-Atlas, Debra, Ilaria, Robert L., Conti, Ilaria, Heathman, Michael, Cronier, Damien M.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2017
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814542/
https://ncbi.nlm.nih.gov/pubmed/28620891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-017-0562-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars